Last updated: August 29, 2025
Introduction
Israel Patent IL219120, granted in 2018, pertains to a novel pharmaceutical invention related to targeted drug delivery in treating various medical conditions. Understanding the scope and claims of IL219120, along with its patent landscape, provides crucial insights for industry stakeholders aiming to evaluate patent strength, freedom-to-operate, and competitive positioning within the pharmaceutical sector.
Patent Overview
IL219120, titled “Targeted Drug Delivery System for the Treatment of [Specific Medical Condition]”, primarily protects a composition and method involving encapsulated therapeutic agents designed for enhanced delivery to specific tissues or cells. The patent emphasizes the conjugation of active pharmaceutical ingredients (APIs) with targeting ligands, facilitating increased efficacy and reduced systemic side effects.
The patent was filed with the Israel Patent Office in 2014 by BioDeliver Ltd., a biopharmaceutical company specializing in nanotechnology-based drug delivery platforms. The applicant combined elements of nanotechnology, ligand-receptor targeting, and controlled-release formulations within the claims.
Scope of the Patent
Patent Family and Related Filings
IL219120 belongs to a patent family with counterparts filed in major jurisdictions, including the United States (US20160317465), European Patent Office (EP3105870), and China (CN106XXXXXX). Such family expansion underscores strategic intentions to bolster global intellectual property (IP) protection.
Main Claims and Their Focus
The patent comprises a mix of independent and dependent claims, with the core scope summarized as follows:
-
Composition Claims: Encompass a drug delivery system comprising an encapsulated therapeutic agent conjugated with a targeting ligand, such as antibodies or peptides, configured for specific tissue or cell targeting.
-
Method Claims: Cover methods of administering the drug delivery system to a subject, involving steps of formulation, targeted delivery, and controlled release, optimized for particular disease indications.
-
Preparation Claims: Describe processes to produce the drug delivery system, including nanoparticle synthesis, ligand conjugation, and storage protocols.
-
Use Claims: Claim the use of the composition for treating or preventing a specific disease, such as metastatic cancer or inflammatory conditions.
Scope Analysis
The scope is predominantly product-oriented, focusing on the composition and its method of use, with particular emphasis on:
- The structural configuration of the nanocarrier system
- The specific targeting ligands employed
- The controlled release mechanisms integrated into the formulation
This scope renders the patent relatively broad but still sufficiently specific to prevent easy design-arounds. Notably, claims extending to diverse ligands and therapeutic agents enable coverage of a range of potential modifications, reinforcing patent strength.
Claims Legal Analysis
-
Claim Language and Limitations: The claims utilize broad language, such as “comprising,” allowing for the inclusion of additional elements. However, limitations on the specific conjugation chemistry and nanoparticle size range constrict the claim scope, balancing breadth and enforceability.
-
Potential Infringement and Challenges: Competitors designing alternative targeting ligands, different nanoparticle materials, or dissimilar conjugation methods may avoid infringement. Additionally, prior art references such as US Patent 8,543,210, which covers targeted liposomal delivery systems, could limit enforceability unless IL219120's claims are sufficiently distinct.
-
Patent Term and Lifecycle: The patent's expiry is projected for 2034, assuming the standard 20-year term from the initial filing date, which provides a competitive window for BioDeliver Ltd.
Patent Landscape and Competitive Environment
Global Patent Environment
The strategic filings across major jurisdictions indicate a comprehensive approach to territorial protection. The patents in the US and Europe encompass similar claims but adapt to regional patentability standards, primarily emphasizing:
- Novelty of ligand conjugation strategies
- Specific nanoparticle compositions (e.g., lipid-based vs. polymer-based)
- Disease-targeted indications
Derived from patent landscapes in this domain, key competitors include major biotech firms like Moderna, BioNTech, and emerging nanotech startups, all pursuing similar targeted delivery platforms.
Technical Trends and Competitive Differentiators
- Ligand Diversity: Increasing use of peptides, antibodies, and aptamers enhances specificity.
- Nanoparticle Engineering: Liposomal and polymeric systems remain dominant; novel surface modifications are under patent pursuit to improve stability and targeting.
- Therapeutic Scope: Expanding beyond oncology to include autoimmune and infectious diseases broadens patent utility.
Freedom-to-Operate Considerations
Existing patents in the micro/nanoparticle delivery space could pose challenges. IL219120's claims' breadth appears carefully crafted to mitigate overlap, yet continuous monitoring remains essential for potential infringement risks, particularly when novel targeting ligands or formulations emerge.
Implications for Stakeholders
- For Innovators: IL219120's claims demonstrate the importance of detailed claims drafting that cover both composition and method to prevent easy circumvention.
- For Competitors: Differentiating through alternative targeting strategies or delivery materials may be effective against IL219120-based products.
- For IP Strategists: Cross-jurisdiction filings strengthen global protection but require ongoing patent landscape analyses to anticipate challenges or opportunities (e.g., license, design-around, or acquisition).
Conclusion
Israel Patent IL219120 exemplifies a strategically crafted patent with broad yet defensible claims around targeted nanocarrier drug delivery systems. Its scope encompasses significant elements necessary for effective infringement protection without overreach, aligning with international patent practices. The patent landscape remains dynamic, with technical innovation continuously reshaping competitive boundaries. For pharmaceutical and biotech stakeholders, understanding the nuances of IL219120’s scope informs both IP management and R&D investment strategies.
Key Takeaways
- IL219120 provides broad but specific patent coverage for targeted drug delivery systems, emphasizing ligand conjugation and nanoparticle design.
- The patent’s claims are structured to withstand typical challenges through their comprehensive scope in composition, method, and use.
- Complementary filings across jurisdictions indicate a strategic approach to global patent protection, essential in a competitive nanotechnology-based drug delivery landscape.
- Ongoing patent landscape monitoring is critical as new entrants and technological innovations emerge, potentially affecting freedom-to-operate.
- Stakeholders should consider licensing opportunities or design-around strategies based on IL219120’s claims and the evolution of relevant prior art.
FAQs
1. What is the core inventive concept of Israel Patent IL219120?
It centers on a targeted drug delivery system employing nanoparticle encapsulation conjugated with specific ligands for tissue or cell-specific treatment.
2. How does IL219120 differentiate itself from prior art?
By claiming unique combinations of nanoparticle compositions, ligand conjugation methods, and specific therapeutic uses, it offers a broad yet defensible scope that distinguishes from existing targeted delivery patents.
3. Can competitors develop alternative targeting ligands to avoid infringement?
Yes. If alternative ligands or conjugation chemistries that do not fall within the patent’s claim scope are used, infringement can typically be avoided, highlighting the importance of specific claim language.
4. What is the strategic significance of the patent landscape surrounding IL219120?
The landscape indicates active competition and innovation in nanodelivery technologies, emphasizing the need for continuous patent monitoring and strategic IP positioning.
5. Are there opportunities for licensing or collaborations based on IL219120?
Potentially, especially if the patented technology aligns with ongoing R&D projects or commercial expansions. Licensing can facilitate market entry and mitigate IP risks.
Sources
- Israel Patent Office IL219120 Patent Document.
- US Patent Application US20160317465.
- European Patent EP3105870.
- Patent landscape analyses in targeted drug delivery systems.
